Treatment of severe pain by morphine, the gold-standard opioid and a potent drug in our arsenal of analgesic medications, is limited by the eventual development of hyperalgesia and analgesic tolerance. We recently reported that systemic administration of a peroxynitrite (PN) decomposition catalyst (PNDC) or superoxide dismutase mimetic attenuates morphine hyperalgesia and antinociceptive tolerance and reduces PN-mediated mitochondrial nitroxidative stress in the spinal cord. These results suggest the potential involvement of spinal PN signaling in this setting; which was examined in the present study. PN removal with intrathecal delivery of manganese porphyrin-based dual-activity superoxide/PNDCs, MnTE-2-PyP 5+ and the more lipophilic MnTnHex-2-PyP 5+ , blocked hyperalgesia and antinociceptive tolerance in rats. Noteworthy is that intrathecal MnTnHex-2-PyP 5+ prevented nitration and inactivation of mitochondrial manganese superoxide dismutase. Mitochondrial manganese superoxide dismutase inactivation enhances the superoxide-to-PN pathway by preventing the dismutation of superoxide to hydrogen peroxide, thus providing an important enzymatic source for PN formation. Additionally, intrathecal MnTnHex-2-PyP 5+ attenuated neuroimmune activation by preventing the activation of nuclear factor kappa B, extracellular-signal-regulated kinase and p38 mitogen activated protein kinases, and the enhanced levels of proinflammatory cytokines, interleukin (IL)-1b and IL-6, while increasing anti-inflammatory cytokines, IL-4 and IL-10. The role of PN was further confirmed using intrathecal or oral delivery of the superoxide-sparing PNDC, SRI-110. These results suggest that mitochondrial-derived PN triggers the activation of several biochemical pathways engaged in the development of neuroinflammation in the spinal cord that are critical to morphine hyperalgesia and tolerance, further supporting the potential of targeting PN as an adjunct to opiates to maintain pain relief.
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Introduction
Effective morphine analgesia is hindered by adaptive changes such as physical dependence, tolerance, addiction, and well-known side effects [15] , as well as by hypersensitivity to noxious and nonnoxious stimuli (ie, hyperalgesia and allodynia) [4] . Understanding the mechanisms that reduce the clinical utility of morphine is relevant for the development of new therapeutic approaches to maintain its effectiveness. We previously reported that peroxynitrite (PN) is essential to morphine antinociceptive tolerance [11, [26] [27] [28] . PN is formed through the reaction of nitric oxide with superoxide [2] and is a potent mediator of nitroxidative stress and inflammation during pain [35] . Once formed, PN reacts irreversibly with many essential biomolecules to induce mitochondrial dysfunction. One such reaction pathway is the selective posttranslational nitration of proteins [41] . We have found that nitration and inactivation of the mitochondrial superoxide regulatory enzyme mitochondrial manganese superoxide dismutase (MnSOD), but not cytosolic copper/zinc SOD (Cu,Zn SOD), occurs in the spinal cord during morphine antinociceptive tolerance and is blocked with systemic PN decomposition catalysts (PNDCs) [26] . PN mediates MnSOD nitration and inactivation, leading to an environment that favors PN formation, which is a feed-forward mechanism we have shown to be critical within the spinal cord during pain [48] . The role of local PN formation in the spinal cord during morphine hyperalgesia and tolerance is unknown. Therefore, in this study,
